Organic Active Ingredients TRIZ Cases

Balanced excipient system increases cannabidiol bioavailability while reducing absorption time through dual circulation routes.

Segmented REIC/Dkk-3 fragments trigger endoplasmic reticulum stress to selectively kill cancer cells while sparing normal tissue.

Extended-release phenserine formulations deliver sustained therapeutic concentrations to prevent anecrotic cell death in neurons following brain trauma.

Combines viral entry inhibitors with RNA polymerase inhibitors to address broad-spectrum effectiveness gaps in current antiviral treatments.

Continuing antidepressant therapy during psilocybin treatment prevents withdrawal symptoms while improving therapeutic safety and efficacy.

Intranasal 2-deoxy-D-glucose inhibits human rhinovirus replication without the side effects of conventional antivirals.

A bioresorbable triblock copolymer forms a quasi-solid depot upon injection without solvents.

High-pressure homogenization stabilizes liposome structures, protecting active ingredients from digestive degradation and increasing bioabsorption rates.

(-)-Epicatechin inhibits FGFR3 signaling to increase femur length, addressing ineffective treatments for FGFR3-related chondrodysplasias.

Iodomethane-D3 simplifies the supply chain by replacing multiple reagents, achieving over 70% yield and 90% purity.

3-pyrimidinyl-4-yl-oxazolidin-2-one compounds inhibit mutant IDH proteins.

Pentosan polysulfate mediates immune response to prevent cytokine-associated toxicity in SARS-CoV-2 infections.

Pre-coating the male luer recess with chlorhexidine acetate creates a lethal concentration that eliminates microbes entering through threaded regions.

NUC-1031 ProTide overcomes cancer stem cell resistance by selectively depleting CD34+/CD123+ leukaemic stem cells.

Hyperstable liposomes encapsulate anti-mitotic agents within a specific lipid and anion matrix to control drug release kinetics.

Consensus DNA vaccines encode universal hemagglutinin sequences to trigger robust immune responses across diverse influenza subtypes.

Non-aqueous solvent crystallization yields stable Form B, eliminating hygroscopic impurities and solvate formation.

Targeted N-terminal modifications of dolastatin 10 enhance solubility without compromising the cytotoxic activity required for cancer treatment.

Polymorph optimization resolves the contradiction between treatment effectiveness and limited therapeutic options for hepatic steatosis.

PEG-Irinotecan prodrug releases active metabolite in vivo, maintaining sustained therapeutic plasma levels while reducing severe diarrheal side effects.

Replacing ethylene-vinyl acetate with low-adsorption polymers preserves active ingredient stability in prostaglandin eye drop containers.

Intranasal esketamine treats depression by targeting biomarker-positive patients, improving effectiveness where conventional treatments fail.

BNC105 eliminates early leukemia progenitor cells to prevent relapse and treatment-related deaths in elderly patients.

Multiple dosage elements feature distinct enteric coatings to ensure consistent mesalamine release in the colon.

Synthesizing fluorinated conjugated polymers overcomes the thickness-resistance trade-off, boosting open circuit voltage and short circuit current.

Poziotinib combined with a VEGFR2 inhibitor delivers synergistic anticancer activity against EGFR and HER2 mutations.

Recombinant retroviral vector delivers immune-stimulating genes to tumor cells.

Novel phenoxy acid compounds inhibit the CIC-1 chloride ion channel to restore neuromuscular transmission.

Amido compounds form covalent bonds with Bruton's tyrosine kinase residues to provide sustained inhibition.

Apolipoprotein A activators elevate ApoA1 levels, inhibiting cancer cell proliferation and metastasis in patients with ABCA1 overexpression.

Synergistic mixture of acylated oligopeptides and troxerutin increases eyelash density at lower concentrations, resolving dermatological safety trade-offs.

Citric acid and sodium citrate maintain pH levels in a citrulline beverage, preventing bad odor generation during storage or heating.

Benzoxazepin oxazolidinone compounds selectively inhibit the PI3Kα isoform, reducing gastrointestinal toxicity associated with broader PI3K inhibition.

Mesoporous silica microparticles in a soluble alginate film release lidocaine for sustained pain relief without manual removal.

Pyridine derivatives bind selectively to cannabinoid receptor 2, resolving the trade-off between therapeutic efficacy and unwanted side effects.

Stabilizers boost intratumoral bioavailability by strengthening adhesion between effector cells and tumor vasculature barriers.

Secondary gas streams injected into spray dryers enhance amorphous solid dispersion bulk density without interfering with the central atomization zone.

Enriching food with light isotopes via fertilizers prevents heavy isotope distortion in proteins, maintaining homeostasis and preventing degenerative diseases.

Isolating specific masticadienonic acid derivatives reduces manufacturing complexity while maintaining efficacy against Alzheimer's disease.

Replacing hazardous reagents with 4-nitrophenol hydrolysis controls regioselectivity and impurities for industrial production.

Segmenting benzazepine structures into azabicyclo cores expands ligand scope and reduces side effects.

Amino-substituted nitrogen-containing fused ring compounds inhibit FGFR kinase activity to address insufficient specificity of existing inhibitors.

A P-glycoprotein inhibitor blocks intestinal efflux to maintain therapeutic docetaxel blood levels without polysorbate 80 excipients.

Selective pyridazinone myosin inhibitors reduce muscle breakdown and inflammation while preserving slow-fiber function in Duchenne Muscular Dystrophy.

Quinazoline compounds bind r(CCUG)exp RNA repeats to disrupt the MBNL1 complex, resolving the trade-off between drug-likeness and therapeutic efficacy.

Segmenting oxymorphone with aryl carboxylic acids delays rapid drug release, reducing abuse potential while maintaining analgesic effectiveness.

LOUP lncRNA recruits RUNX1 to form active chromatin loops and induce PU.1 expression in myeloid cells.

Cationic and hydrophilic polymer chains resolve dry eye contradictions by sustaining tear film stability while preventing bacterial adhesion.

Formula I compounds inhibit Olig2 activity to reduce systemic toxicity while extending survival in glioblastoma treatment.

Synthetic duplex microRNA mimetics modulate TP53 pathway activity to inhibit cell division, addressing complex TP53 mutation detection challenges.